Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing

BACKGROUND: The pre‐adjuvant chemotherapy (PAC) status of postoperative pancreatic ductal adenocarcinoma (PDAC) patients has not been studied and elaborated well previously. METHOD: The association of PAC variables and prognoses was explored using a multivariable Cox model, restricted cubic spline a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Ningzhen, Qin, Kai, Li, Jingfeng, Jin, Jiabin, Jiang, Yu, Deng, Xiaxing, Shen, Baiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487870/
https://www.ncbi.nlm.nih.gov/pubmed/35434972
http://dx.doi.org/10.1002/cam4.4698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487870/
https://www.ncbi.nlm.nih.gov/pubmed/35434972
http://dx.doi.org/10.1002/cam4.4698

Ejemplares similares